ChromaDex to Present at the Lytham Partners Spring 2023 Investor Conference
11 Mayo 2023 - 7:34AM
Business Wire
ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company
dedicated to healthy aging, today announced that its Chief
Executive Officer, Rob Fried, and Chief Financial Officer, Brianna
Gerber, will be participating in the Lytham Partners Spring 2023
Investor Conference.
Mr. Fried and Mrs. Gerber will be participating in virtual
one-on-one meetings throughout the event on Thursday, May 18,
2023.
To arrange a meeting with the ChromaDex management team, please
contact Lytham Partners at 1x1@lythampartners.com, or register
online by clicking the link here: ChromaDex Investor Meetings -
Lytham Partners.
For additional information on ChromaDex, visit
www.chromadex.com.
About ChromaDex:
ChromaDex Corp. is a global bioscience company dedicated to
healthy aging. The ChromaDex team, which includes world-renowned
scientists, is pioneering research on nicotinamide adenine
dinucleotide (NAD+), levels of which decline with age. ChromaDex is
the innovator behind NAD+ precursor nicotinamide riboside (NR),
commercialized as the flagship ingredient Niagen®. Nicotinamide
riboside and other NAD+ precursors are protected by ChromaDex’s
patent portfolio. ChromaDex maintains a website at
www.chromadex.com to which ChromaDex regularly posts copies of its
press releases as well as additional and financial information
about the Company.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230511005158/en/
ChromaDex Media Contact: Kendall Knysch, Director of
Media Relations 310-388-6706 ext. 689
kendall.knysch@chromadex.com
ChromaDex Investor Relations Contact: +1 (949) 356-1620
InvestorRelations@ChromaDex.com
ChromaDex (NASDAQ:CDXC)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
ChromaDex (NASDAQ:CDXC)
Gráfica de Acción Histórica
De May 2023 a May 2024